Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic and epigenetic profiling of CLL disease progression reveals limited somatic evolution and suggests a relationship to memory-cell development.

Blood cancer journal·2015

Same author

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.

The Journal of infectious diseases·2001

Same author

The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment.

The Journal of infectious diseases·2000

Same author

HIV-1 neurocognitive disorders and chemokine receptors.

AIDS (London, England)·1997

Same author

The proteins encoded by the rbs operon of Escherichia coli: I. Overproduction, purification, characterization, and functional analysis of RbsA.

Protein science : a publication of the Protein Society·1996

Same author

Constitutive phosphorylation of I kappa B alpha by casein kinase II.

Proceedings of the National Academy of Sciences of the United States of America·1995

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Miscreant myeloproliferative disorder stem cells.

C H M Jamieson¹, C F Barroga, W P Vainchenker

¹Department of Medicine, Moores UCSD Cancer Center San Diego Medical Center, University of California, La Jolla, CA 92093-0820, USA. cjamieson@ucsd.edu

|October 17, 2008

Summary

Myeloproliferative disorders (MPDs) originate from hematopoietic stem cells (HSCs) and can progress to acute leukemia. Targeting molecular mutations like JAK2V617F is crucial for developing effective MPD therapies.

More Related Videos

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Pan-myeloid Differentiation of Human Cord Blood Derived CD34⁺ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

Related Experiment Videos

Last Updated: Jun 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Pan-myeloid Differentiation of Human Cord Blood Derived CD34⁺ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

Area of Science:

Hematology
Molecular Biology
Oncology

Background:

Myeloproliferative disorders (MPDs) are characterized by excessive blood cell production and can transform into acute leukemia.
Hematopoietic stem cell (HSC) origin of MPDs is established, with recent focus on HSC-specific molecular mutations.
Chronic myeloid leukemia (CML) driven by BCR-ABL led to targeted therapies, but resistant HSCs remain a challenge.

Purpose of the Study:

Investigate the molecular mechanisms driving MPD pathogenesis, particularly in BCR-ABL-negative cases.
Understand the role of JAK2 mutations in MPD development and leukemic transformation.
Identify strategies to redirect aberrant MPD stem cells towards normal differentiation.

Main Methods:

Review of recent studies on molecular mutations in MPDs.
Analysis of JAK2V617F mutation's role in BCR-ABL-negative MPDs.
Examination of stem cell differentiation and survival pathways in MPD.

Main Results:

JAK2 activation, specifically the JAK2V617F mutation, is central to BCR-ABL-negative MPD pathogenesis.
Acquired mutations disrupt HSC differentiation and survival, leading to self-renewing progenitors.
These aberrant progenitors contribute to leukemic stem cell generation and transformation.

Conclusions:

Targeting molecular pathways in MPDs is essential for preventing leukemic transformation.
Combined therapies may be necessary to address the complexity of MPD stem cell dysfunction.
Further research into JAK2 signaling and stem cell behavior is critical for therapeutic advancements.